A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00195780
First received: September 14, 2005
Last updated: June 29, 2007
Last verified: June 2007
  Purpose

The purpose of the study is to evaluate the long-term safety profile of the Investigational Medication Depakote ER in the treatment of Bipolar I Disorder, manic or mixed episode, in children and adolescents ages 10-17.


Condition Intervention Phase
Bipolar I Disorder
Drug: Divalproex Sodium (Depakote ER)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Safety

Secondary Outcome Measures:
  • Y-MRS
  • CGI-S
  • C-GAS
  • CDRS-R
  • CGSQ
  • responders
  • remitters

Enrollment: 227
Study Start Date: February 2005
  Eligibility

Ages Eligible for Study:   10 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is between 10 and 17 years of age, inclusive, on Day 1 and weighs at least 60 lbs (27 kg).
  • Subject has a current psychiatric diagnosis of bipolar I disorder, manic or mixed episode, based on the K-SAD-PL interview and DSM-IV-TR criteria.
  • Subject is an outpatient in a manic or mixed episode with a YMRS score of greater than or equal to 16 during Screening and at Day 1.

Exclusion Criteria:

  • Has an Axis I disorder other than Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), Panic Disorder, Enuresis, Encopresis, Parasomnias, Agoraphobia, Specific Phobia, Social Phobia or Separation Anxiety Disorder; or subject has an Axis II disorder that would interfere with the subject's ability to comply with study procedures or confound interpretation of the study results. Subject meets DSM-IV-TR criteria for substance abuse within the month prior to Screening, or meets the criteria for substance dependence within the three months prior to Screening, or exhibits signs of drug or alcohol intoxication or withdrawal at Day 1.
  • Is expected to require hospitalization for the current manic or mixed episode.
  • Is violent, homicidal, or suicidal such that, in the opinion of the investigator, the subject is at significant imminent risk of hurting self or others.
  • Has a history of a chronic or acute medical disorder that, in the opinion of the investigator, would preclude compliance with the protocol, or confound interpretation of the study results.
  • Has a history of, or is suspected of having a seizure disorder.
  • Has any central nervous system (CNS) neoplasm, CNS infection, demyelinating disease, degenerative neurological disease, or any progressive CNS disease.
  • Has Platelet count less than or equal to 100,000/µL
  • Has blood chemistry ALT/AST value(s) greater than or equal to 2 times upper limit of normal at screening.
  • Is taking a protocol allowed medication for ADHD that has not been stable for at least 3 months prior to Day 1, or that, in the investigator's opinion, may be exacerbating mood symptoms.
  • Requires anticoagulant drug therapy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00195780

  Hide Study Locations
Locations
United States, California
PCSD Feighner Research
San Diego, California, United States, 92111
PCSD Feighner Research
San Marcos, California, United States, 92078
United States, Florida
Altamonte Springs, Florida, United States, 32701
Segal Institute for Clinical Research
Ft. Lauderdale, Florida, United States, 33319
Sarkis Clinical Trials
Gainesville, Florida, United States, 32607
Segal Institute for Clinical Research
North Miami, Florida, United States, 33161
Kolin Research Group
Winter Park, Florida, United States, 32789
United States, Georgia
Northlake Medical Research Center
Decatur, Georgia, United States, 30033
United States, Idaho
Mountain West Clinical Trials
Eagle, Idaho, United States, 83616
United States, Illinois
Capstone Clinical Research
Libertyville, Illinois, United States, 60048
United States, Indiana
Clinco
Terre Haute, Indiana, United States, 47802
United States, Kansas
Cientifica Inc.
Newton, Kansas, United States, 67114
Psychiatric Associates
Overland Park, Kansas, United States, 66211
United States, Louisiana
Brentwood Research Institute
Shreveport, Louisiana, United States, 71101
United States, Maine
Acadia Hospital
Bangor, Maine, United States, 04402-0422
United States, Maryland
Pharmasite Research
Baltimore, Maryland, United States, 21208
United States, North Carolina
North Carolina Neuropsychiatry, PA
Chapel Hill, North Carolina, United States, 27514
United States, North Dakota
Odyssey Research
Fargo, North Dakota, United States, 58104
United States, Ohio
Neuro Behavioral Clinical Research, INC.
Canton, Ohio, United States, 44708
Psychiatric Professional Services
Cincinnati, Ohio, United States, 45267-0559
Rakesh Ranjan, M.D. & Associates, Inc.
Lyndhurst, Ohio, United States, 44124
United States, Oklahoma
IPS Research
Oklahoma City, Oklahoma, United States, 73103
Cutting Edge Research Group
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
Clinical Trials Specialists
Bala Cynwyd, Pennsylvania, United States, 19004-1604
United States, Tennessee
UTHSC, Sept. of Psychiatry, College of Medicine
Memphis, Tennessee, United States, 38105
United States, Texas
InSite Clinical Research
DeSoto, Texas, United States, 75115
Red Oak Psychiatry
Houston, Texas, United States, 77090
R/D Clinical Research
Lake Jackson, Texas, United States, 77566
United States, Washington
Northwest Clinical Research Center
Bellevue, Washington, United States, 98004
Sponsors and Collaborators
Abbott
Investigators
Study Director: Global Medical Information Abbott
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00195780     History of Changes
Other Study ID Numbers: M03-647
Study First Received: September 14, 2005
Last Updated: June 29, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Abbott:
Bipolar I Disorder
Depakote

Additional relevant MeSH terms:
Valproic Acid
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs

ClinicalTrials.gov processed this record on June 17, 2013